Trials / Enrolling By Invitation
Enrolling By InvitationNCT03972345
Influence of Adherence to Growth Hormone Therapy (GHT) With Norditropin® on Near Final Height in Patients With Growth Hormone Deficiency (GHD) and Born Small for Gestational Age (SGA)
A Non-interventional, Prospective Study in Germany to Investigate the Influence of Adherence to Growth Hormone Therapy (GHT) With Norditropin® on Near Final Height in a Patient Population With Isolated Growth Hormone Deficiency (GHD) and Born Small for Gestational Age (SGA)
- Status
- Enrolling By Invitation
- Phase
- —
- Study type
- Observational
- Enrollment
- 750 (estimated)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 0 Years – 15 Years
- Healthy volunteers
- Not accepted
Summary
Participants are free to decide if they want to take part in this study or not. The study will be conducted to collect information about the influence of adherence to growth hormone therapy with Norditropin® in children and teenagers in daily practice in Germany. This study will look mainly at the difference in near final height between children and teenagers who adhere to their therapy plan with Norditropin® to non-adherent patients. Participants will get Norditropin® as prescribed to them by their doctor. The study will last as long as the therapy with growth hormone is seen necessary by the participants' doctors and the participants, up to a maximum of 10 years. During the visits at the participants' doctors participants will be asked to fill in a questionnaire.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Norditropin® FlexPro® | Patients will be treated with commercially available Norditropin® FlexPro® according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Norditropin® FlexPro® has been made by the treating physician and the patient's parents/legal guardian before and independently of the decision to include the patient in this study. |
Timeline
- Start date
- 2019-06-21
- Primary completion
- 2029-06-30
- Completion
- 2031-06-30
- First posted
- 2019-06-03
- Last updated
- 2025-09-25
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT03972345. Inclusion in this directory is not an endorsement.